Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03897881 · ClinicalTrials.gov registry record · Phase 2
An Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Participants With High-Risk Melanoma (KEYNOTE-942)
A Phase 2 study of Melanoma, sponsored by ModernaTX.
- Active
- Registry status
- Phase 2
- Development phase
- 267
- Enrollment target
- 20
- Study locations
NCT03897881 is a Phase 2 study of Melanoma that is active but no longer recruiting, run by ModernaTX. The registered enrollment target is 267 participants, below the 706-participant average among 266 other Melanoma trials with a reported enrollment target (62% lower). The trial reports 20 study locations across 17 states.
The verdict
NCT03897881, a Phase 2 study of Melanoma, is active but no longer recruiting, sponsored by ModernaTX.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 267 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to assess whether postoperative adjuvant therapy with mRNA-4157 and pembrolizumab improves recurrence free survival (RFS) compared to pembrolizumab alone in participants with complete resection of cutaneous melanoma and a high risk of recurrence.
Conditions Studied
Interventions
- BIOLOGICAL Pembrolizumab
- DRUG mRNA-4157
Study Locations (20)
California
- California Pacific Medical Center Research Institute -CPMCRI - San Francisco
- Angeles Clinic and Research Institute - Santa Monica
Massachusetts
- Massachusetts General Hospital - Boston
- Dana Farber Cancer Institute - Boston
New South Wales
- Melanoma Institute Australia - North Sydney
- Westmead Hospital - Westmead
Arizona
- University of Arizona - Tucson
Colorado
- University of Colorado Cancer Center - Aurora
Connecticut
- Smilow Cancer Center at Yale New Haven Hospital - New Haven
District of Columbia
- Lombardi Cancer Center - Washington D.C.
Florida
- Orlando Health UF Health Cancer Center - Orlando
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 267 participants |
| Start Date | 2019-07-18 |
| Est. Completion | 2032-11-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03897881
The ClinicalTrials.gov registry entry for NCT03897881 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 267 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 706-participant average among 266 other Melanoma trials with a reported enrollment target (62% lower). The listed sponsor is ModernaTX, which has 90 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Melanoma appearing as the primary indexed condition, and to 2 interventions - of which Pembrolizumab is the first listed.
NCT03897881 reports 20 study locations spanning 17 distinct geographic areas - top geographies include California, Massachusetts, New South Wales.
Frequently Asked Questions
What is clinical trial NCT03897881 about?
NCT03897881 is a clinical study titled "An Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Participants With High-Risk Melanoma (KEYNOTE-942)". The purpose of this study is to assess whether postoperative adjuvant therapy with mRNA-4157 and pembrolizumab improves recurrence free survival (RFS) compared to pembrolizumab alone in participants with complete resection of cutaneous melanoma and a high risk of recurrence.
What is the current status of trial NCT03897881?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 267 participants. The study started on 2019-07-18. Estimated completion is 2032-11-30.
What conditions does trial NCT03897881 study?
This clinical trial studies the following conditions: Melanoma.
What interventions are being tested in trial NCT03897881?
The interventions under investigation include: Pembrolizumab (BIOLOGICAL), mRNA-4157 (DRUG).
Who is sponsoring clinical trial NCT03897881?
This trial is sponsored by ModernaTX, which has 90 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03897881 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Connecticut, District of Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Melanoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies
RECRUITING · Phase 2
-
Neoadjuvant Immune Checkpoint Blockade + a Prebiotic Food-enriched Dietary Intervention to Optimize Immune Response in Melanoma: NEO-PreFED
RECRUITING · Phase 2
-
Zimberelimab (AB122) With TIGIT Inhibitor Domvanalimab (AB154) in PD-1 Relapsed/Refractory Melanoma
RECRUITING · Phase 2
-
A Study of IBI363 in Subjects with Advanced Solid Malignancies
RECRUITING · Phase 2
-
A Phase 2 Trial for Metastatic Melanoma Using Adoptive Cell Therapy With Tumor Infiltrating Lymphocytes Plus IL-2 Either Alone or Following the Administration of Pembrolizumab
RECRUITING · Phase 2
-
Neoadjuvant and Adjuvant Anti-PD1 or Combinations for Locoregionally Advanced Melanoma
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.